Enrollment completion with strong demand signals high investigator and patient interest, reducing clinical risk. Monitor for early 2027 data readout and any financing updates for the pivotal study. The rapid enrollment may accelerate timelines and increase partnership interest.
Drug in focus
DRTS drug pipeline →Alpha DaRT
▲ Bullish Named in this 6-K- Impact
- Phase
- Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
- Time to market
- The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
- Next catalyst
- None dated
What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 31 $14.11entry
- T+1 · 3mo ago −1.06%α −0.38% · $13.96
- T+5 · 2mo ago +5.17%α +5.32% · $14.84
- T+20 · 7w ago +7.65%α +7.84% · $15.19
- T+54 · todayOpen
- T+60 · in 7d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau completed enrollment in its IMPACT pilot study of Alpha DaRT for pancreatic cancer, enrolling 48 patients (4x the original 12) after three expansions driven by strong demand. This de-risks the pancreatic program and supports the design of a planned pivotal study, with initial data expected in early 2027. The filing is a positive clinical milestone for a pre-commercialization company with a $1.4B market cap and strong analyst consensus.
Key Facts
- IMPACT study enrolled 48 patients, expanded three times from original 12-patient design
- Study conducted under U.S. IDE across 10 centers in US, Canada, and Israel
- Alpha DaRT delivered as one-time add-on to first-line chemotherapy (mFOLFIRINOX or gemcitabine + nab-paclitaxel)
- Initial data targeted for early 2027 to inform pivotal study design
- Global pancreatic program includes ACAPELLA trial in France and University of Verona study
- Pancreatic cancer is third leading cause of cancer death in US with ~66,000 new cases/year
Financial Impact
No financial data in filing; milestone de-risks pipeline for a pre-revenue company with $1.4B market cap
Risk Factors
- Pilot study only; no efficacy data yet, results may not support pivotal design
- Alpha DaRT not approved for any indication; regulatory path uncertain
- Company likely needs additional capital to fund pivotal study and operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-095370 |
| Document: ea0303693-6k_alpha.htm | 0001213900-26-095370 |
| Document: 0001213900-26-095370-index-headers.html | 0001213900-26-095370 |
| Document: 0001213900-26-095370-index.html | 0001213900-26-095370 |
| Document: 0001213900-26-095370.txt | 0001213900-26-095370 |
Track record
25 reports on DRTS
9 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 11 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers